Repetitive infusion of levosimendan in patients with chronic heart failure: A meta-analysis

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 895-901

  Yi, Gui Yan ^a   Li, Jun Xia ^a   Zhang, Jian ^a   Niu, Li Li ^a   Zhang, Cai Yun ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Heart failure; Meta analysis; Treatment outcome

Indexed keywords

DOBUTAMINE; FUROSEMIDE; LEVOSIMENDAN; PLACEBO; PROSTAGLANDIN E1; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ARTICLE; DRUG INFUSION; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; META ANALYSIS; MORTALITY; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); HEART STROKE VOLUME; PATHOPHYSIOLOGY;

CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; HYDRAZONES; PYRIDAZINES; STROKE VOLUME;

EID: 84925848775     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.893736     Document Type: Article

References (27)

1. Packer M, Coats AJ, Fowler MB et al: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001; 344: 1651-58
2. Rouleau JL, Roecker EB, Tendera M et al: Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: The carvedilol prospective randomized cumulative survival (copernicus) study. J Am Coll Cardiol, 2004; 43: 1423-29
3. Hunt SA, Abraham WT, Chin MH et al: 2009 focused update incorporated into the acc/aha 2005 guidelines for the diagnosis and management of heart failure in adults: A report of the american college of cardiology foundation/american heart association task force on practice guidelines: Developed in collaboration with the international society for heart and lung transplantation. Circulation, 2009; 119: e391-479
4. Felker GM, O’Connor CM: Inotropic therapy for heart failure: An evidencebased approach. Am Heart J, 2001;142: 393-401
5. Rapezzi C, Bracchetti G, Branzi A, Magnani B: The case against outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant, 2000; 19: S58-63
6. Gheorghiade M, Teerlink JR, Mebazaa A: Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol, 2005; 96: 68G-73G
7. Haikala H, Kaheinen P, Levijoki J, Linden IB: The role of camp-and cgmpdependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res, 1997; 34: 536-46
8. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N: The novel calcium sensitizer levosimendan activates the atp-sensitive k+ channel in rat ventricular cells. J Pharmacol Exp Ther, 1997; 283: 375-83
9. Ukkonen H, Saraste M, Akkila J et al: Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther, 2000; 68: 522-31
10. Tasal A, Demir M, Kanadasi M et al: Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure. Med Sci Monit, 2014; 20: 276-82
11. Nieminen MS, Altenberger J, Ben-Gal T et al: Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. Int J Cardiol, 2014; 174: 360-67
12. Altenberger J, Parissis JT, Costard-Jaeckle A et al: Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (levorep) study: A multicentre randomized trial. Eur J Heart Fail, 2014; 16: 898-906
13. Mavrogeni S, Giamouzis G, Papadopoulou E et al: A 6-month follow-up of intermittent levosimendan administration effect on systolic function, specific activity questionnaire, and arrhythmia in advanced heart failure. J Card Fail, 2007; 13: 556-59
14. Kleber FX, Bollmann T, Borst MM et al: Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: Results of a pilot study. J Clin Pharmacol, 2009; 49: 109-15
15. Parissis JT, Adamopoulos S, Farmakis D et al: Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart, 2006; 92: 1768-72
16. Levin RP, Tanus R, Degrange M: Abstract 3815: The intermittent infusion of levosimendan reduces mortality and re-admissions in patients with advanced heart failure. Circulation, 2009; 120: S865
17. Bonios MJ, Terrovitis JV, Drakos SG et al: Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol, 2012; 159: 225-29
18. Malfatto G, Della Rosa F, Villani A et al: Intermittent levosimendan infusions in advanced heart failure: Favourable effects on left ventricular function, neurohormonal balance, and one-year survival. J Cardiovasc Pharmacol, 2012; 60: 450-55
19. Berger R, Moertl D, Huelsmann M et al: Levosimendan and prostaglandin e1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail, 2007; 9: 202-8
20. Silvetti S, Greco T, Di Prima AL et al: Intermittent levosimendan improves mid-term survival in chronic heart failure patients: Meta-analysis of randomised trials. Clin Res Cardiol, 2014; 103: 505-13
21. Thackray S, Easthaugh J, Freemantle N, Cleland JG: The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail, 2002; 4: 515-29
22. Mebazaa A, Nieminen MS, Filippatos GS et al: Levosimendan vs. Dobutamine: Outcomes for acute heart failure patients on beta-blockers in survive. Eur J Heart Fail, 2009; 11: 304-11
23. Antila S, Sundberg S, Lehtonen LA: Clinical pharmacology of levosimendan. Clin Pharmacokinet, 2007; 46: 535-52
24. Figgitt DP, Gillies PS, Goa KL: Levosimendan. Drugs, 2001; 61: 613-27; discussion 628-29
25. Erdei N, Papp Z, Pollesello P et al: The levosimendan metabolite or-1896 elicits vasodilation by activating the k(atp) and bk(ca) channels in rat isolated arterioles. Br J Pharmacol, 2006; 148: 696-702
26. McMurray JJ, Adamopoulos S, Anker SD et al: Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the heart failure association (hfa) of the esc. Eur J Heart Fail, 2012; 14: 803-69
27. Papp Z, Edes I, Fruhwald S et al: Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012; 159: 82-87